Piper Sandler analyst Allison Bratzel maintained a Buy rating on Argenx Se (ARGX – Research Report) today and set a price target of $522.00. The company’s shares closed yesterday at $368.60.
According to TipRanks, Bratzel is a 2-star analyst with an average return of 0.0% and a 42.22% success rate. Bratzel covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Akebia Therapeutics, and Codexis.
In addition to Piper Sandler, Argenx Se also received a Buy from Bank of America Securities’s Tazeen Ahmad in a report issued on April 19. However, on April 18, William Blair maintained a Hold rating on Argenx Se (NASDAQ: ARGX).
The company has a one-year high of $550.76 and a one-year low of $327.73. Currently, Argenx Se has an average volume of 292.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Argenx Se (ARGX) Company Description:
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Read More on ARGX:
- Argenx’s VYVGART Shows Promising CIDP Treatment Results
- Argenx presents data from ADHERE trial evaluating Vyvgart Hytrulo
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- Immunovant initiated with an Outperform at Oppenheimer
